Tirzepatide, a novel medication that mimics the action of two hormones involved in blood sugar regulation, has shown promising results in clinical trials, leading to significant weight loss and improved glycemic control among patients with type 2 diabetes
The alterations in substrate metabolism during heart failure, whether they result from the disease or represent residual compensatory responses within the body, remain controversial
For most patients, gastrointestinal side effects are most pronounced in the first two to eight weeks of treatment and improve substantially as the body adjusts
Available online at: (accessed April, 2026)
Only the scale markings on the barrel differ
1 However, the introduction of Wegovy 7.2 mg means both medications support similar weight loss at their highest dose